Trial reportObesity surgery2022
Standard Biliopancreatic Limb (50 cm) Roux-en-Y Gastric Bypass Versus Long Biliopancreatic Limb (100 cm) Roux-en-Y Gastric Bypass in Patients with Body Mass Index 40-50 kg/m
Trial report in Obesity surgery, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 3 syntheses or guidelines pooled it, 19 citations in OpenAlex.
- Pooled it
- Therapeutic Options for Recurrence of Weight and Obesity Related Complications After Metabolic and Bariatric Surgery: An IFSO Position Statement.Obesity surgery · 2024Guideline
- Optimal Small Bowel Limb Lengths of Roux-en-Y Gastric Bypass.Current obesity reports · 2023Pooled it
- Long Biliopancreatic Limb (BPL) RYGB Versus Short BPL RYGB Post-Suboptimal Initial Clinical Response of SG or Recurrent Weight Gain: A Randomized Controlled Study.Obesity surgery · 2025Trial
- Gut microbiota alterations induced by Roux-en-Y gastric bypass result in glucose-lowering by enhancing intestinal glucose excretion.Gut microbes · 2025Article
- Enhanced Total Weight Loss 2 Years Post-Roux-en-Y Gastric Bypass with Longer Biliopancreatic Limb.Obesity surgery · 2025Article
- Early Surgical Outcomes of Metabolic and Bariatric Surgery for Super Obesity in Korean Morbidly Obese Patients.Journal of metabolic and bariatric surgery · 2025Article
- A Longer Biliopancreatic Limb and Shorter Common Channel Enhance Weight Loss But May Have Harmful Effects in Mouse Models of Roux-en-Y Gastric Bypass.Obesity surgery · 2025Article
- Previous Body-Contouring Surgery Before Metabolic and Bariatric Surgery: Does It Matter?Obesity surgery · 2023Article
- Roux-en-Y and One-Anastomosis Gastric Bypass Surgery Are Superior to Sleeve Gastrectomy in Lowering Glucose and Cholesterol Levels Independent of Weight Loss: a Propensity-Score Weighting Analysis.Obesity surgery · 2023Article
- Are the Common Statistics Used in the Bariatric Surgery Always Valid to Be Relied on?Obesity surgery · 2023Article
- Comment on "Effectiveness of Roux‑en‑Y Gastric Bypass vs Sleeve Gastrectomy on Lipid Levels in Type 2 Diabetes: a Meta‑analysis".Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract · 2022Article
Corrections and comments
- Commented on by
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRoux-en-Y gastric bypass (RYGB) is a widely performed procedure worldwide especially with the presence of associated medical conditions. Patients with body mass index (BMI) 40-50 kg/m STUDY
designhundred-and-fifty patients with BMI between 40 and 50 kg/m
resultsOnly 64/75 patients in S-RYGB and 57/75 patients in L-RYGB completed the study. L-RYGB had faster weight loss, higher %TWL, and less BMI than S-RYGB with the maintenance of achieved weight. L-RYGB had better control of DM and dyslipidemia than S-RYGB. There were no significant differences in nutritional status between S-RYGB and L-RYGB rather than lower levels of calcium and Hb and higher levels of PTH in L-RYGB yet they remain within the normal range.
conclusionThe application of L-RYGB helps in achieving faster weight loss for a longer period with better remission of associated comorbidities as DM, HTN, and dyslipidemia in patients with BMI 40-50 kg/m
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.